837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro von Uddbäck, Ida, Fritzell, Sara, Ljung, Lill, Nilsson, Anneli, Celander, Mona, Shetty, Amulya Krishna, Andersson, Hampus, Jimenez, David Gomez, Levin, Mattias, Lindstedt, Malin, Hägerbrand, Karin, Sundstedt, Anette, Ellmark, Peter

Volltext

Abstract 2939: ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo von Hägerbrand, Karin, Sundstedt, Anette, Levin, Mattias, de Coaña, Yago Pico, Varas, Laura, Ljung, Lill, Nilsson, Anneli, Celander, Mona, Jimenez, David Gomez, Andersson, Hampus, Lindstedt, Malin, Ellmark, Peter

Volltext

Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects von Sundstedt, Anette, Celander, Mona, Hedlund, Gunnar

Volltext

Abstract B17: Immunomodulation by tasquinimod: Combination with immunotherapy results in enhanced CD8 T cell responses and improved antitumor effects von Sundstedt, Anette, Olsson, Anders, Stenström, Martin, Celander, Mona, Törngren, Marie, Eriksson, Helena, Hedlund, Gunnar, Liberg, David, Leanderson, Tomas

Volltext

Monotherapeutically Nonactive CTLA-4 Blockade Results in Greatly Enhanced Antitumor Effects When Combined With Tumor-targeted Superantigens in a B16 Melanoma Model von SUNDSTEDT, Anette, CELANDER, Mona, ERIKSSON, Helena, TÖRNGREN, Marie, HEDLUND, Gunnar

Volltext

Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects von Sundstedt, Anette, Celander, Mona, Öhman, Marie Wallén, Forsberg, Göran, Hedlund, Gunnar

Volltext

The limbic functional selectivity of amperozide is not mediated by dopamine D 2 receptors as assessed by in vitro and in vivo binding von Svartengren, Jan, Celander, Mona

Volltext